A Randomized, Double-blind, 2-way Crossover, Placebo-controlled Study to Investigate the Influence of a Single-dose of Moxifloxacin on the QTc Interval in Healthy Male and Female Subjects for Positive Control Validation in Selected Centers of the PATENT-1 Trial.

Trial Profile

A Randomized, Double-blind, 2-way Crossover, Placebo-controlled Study to Investigate the Influence of a Single-dose of Moxifloxacin on the QTc Interval in Healthy Male and Female Subjects for Positive Control Validation in Selected Centers of the PATENT-1 Trial.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2013

At a glance

  • Drugs Moxifloxacin (Primary)
  • Indications Acute exacerbations of chronic bronchitis; Acute sinusitis; Community-acquired pneumonia; Intra-abdominal infections; Pelvic inflammatory disorders; Respiratory tract infections; Skin and soft tissue infections; Tuberculosis
  • Focus Pharmacodynamics
  • Sponsors Bayer
  • Most Recent Events

    • 16 Sep 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 16 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Dec 2009 Planned number of patients changed from 60 to 50 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top